Semaglutide – Oral

Product Description:

The oral formulation of Semaglutide is a GLP-1 receptor agonist in tablet form. It mimics the action of incretin hormones to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. It is used for the treatment of type 2 diabetes to help control blood glucose and can also support weight management. It has been approved by the U.S. FDA, the European EMA, and multiple regulatory agencies worldwide for adult patients with type 2 diabetes.

Active Ingredient: Semaglutide
Dosage Form: Oral tablet
Dosing Frequency: Once daily. Each dosage strength contains three boxes, each with 10 tablets, providing 30 days of treatment.
Brand Name: Rybelsus
Generic Name: Semaglo
Manufacturer (Generic): Ziska Pharmaceuticals

Indications:

Oral Semaglutide is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. It can also reduce major cardiovascular events in patients at cardiovascular risk and is suitable for long-term weight management in overweight or obese individuals.

Dosage and Administration:

Take once daily in the morning, at least 30 minutes before the first meal or any other oral medications, with a small amount of water (no more than 120 ml). The starting dose is 3 mg daily for 30 days, then increased to 7 mg. If glycemic control remains insufficient, the dose may be further increased to 14 mg daily. Follow physician guidance for dose adjustments.

Side Effects:

Common side effects of oral Semaglutide include nausea, stomach discomfort, indigestion, acid reflux, abdominal pain, bloating, constipation, taste changes, and fatigue. In rare cases, severe allergic reactions may occur. Side effects vary among individuals; close observation is recommended during initial treatment.

Storage Conditions:

Store below 30°C in a cool, dry place, protected from light, and keep out of reach of children.

Frequently Asked Questions:

Q: Is the oral Semaglutide sold by Mediva Rx the original brand?
A: No. Mediva Rx offers a generic medication manufactured by one of the top ten pharmaceutical companies in Bangladesh. It contains the same active ingredient and therapeutic effect as the original brand. It has passed testing by the Directorate General of Drug Administration (DGDA) and is legally registered for sale.

Q: Is the manufacturer of the oral Semaglutide reliable?
A: Yes. Our partner manufacturer, Ziska Pharmaceuticals, is a leading top-ten pharmaceutical company in Bangladesh, equipped with in-house R&D, production facilities, and quality-control laboratories. It complies with international pharmaceutical manufacturing standards.

Q: What is the difference between the oral and injectable versions of Semaglutide?
A: Both contain the same active ingredient, Semaglutide, and are used for type 2 diabetes treatment and weight management. The difference lies in dosing: the oral version is taken daily, while the injectable version is administered once weekly. The choice depends on patient preference, treatment goals, and medical guidance.

Q: Which provides better weight-loss results, the oral or injectable version?
A: The injectable version provides stronger weight-loss outcomes. Clinical trial data show that injections can reduce body weight by approximately 12–15% over 68 weeks, whereas the oral version results in 4–6% weight loss over 52 weeks. The main reason is that injections maintain more stable drug concentration, while oral absorption is limited by the gastrointestinal tract.

Disclaimer:

This information is for reference only. Treatment decisions should follow physician guidance and the official prescribing information.

Prescribing Information:

Download Link